{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:06:44Z","timestamp":1788944804951,"version":"build-2803163510"},"reference-count":53,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background. Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cell immunotherapy (CARTx) and subsequent T cell dysfunction increase risk for infection. However, it is difficult to discern infection from CRS in the early (up to Day 30) and late (Days 31\u2013180) periods after CARTx due to overlapping signs and symptoms. Methods. We analyzed infectious complications and predictors of infection during the early and late periods after CARTx in 213 adult patients with malignancies over a 5-year period. Results. Overall, 75 patients (35%) had at least one infection, mostly within the first 30 days after CARTx. Infections occurring early after CARTx were mostly bacterial, whereas viral infections predominated after Day 30. In multivariate analyses, a high baseline CRP (\u22655 mg\/dL) was significantly associated with increased risk of infection in the early period after CARTx, and a Day-5-to-baseline-CRP ratio of &lt;1.5 was significantly associated with a higher risk of infection through all 180 days after CARTx and during the late period after CARTx. Conclusions. Infections in adult patients are common up to 180 days after receiving CARTx. High baseline CRP without significant temporal changes may predict risk of infection. Tracking CRP trends may be a useful clinical tool for discerning causes of fever and guiding antibiotic stewardship in this population at high risk for infections.<\/jats:p>","DOI":"10.3390\/cancers18182915","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:05:43Z","timestamp":1788941143000},"page":"2915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1346-9388","authenticated-orcid":false,"given":"Poonam","family":"Mathur","sequence":"first","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hegang","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-6406","authenticated-orcid":false,"given":"David J.","family":"Riedel","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Holland","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-377X","authenticated-orcid":false,"given":"Danica","family":"Palacio","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-6634","authenticated-orcid":false,"given":"Jacqueline T.","family":"Bork","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-4657","authenticated-orcid":false,"given":"Katya","family":"Prakash","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine, Northwell Health, Manhasset, NY 11030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hardy","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet","family":"Kocoglu","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Fromowitz","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Yared","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Baddley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s44313-026-00145-2","article-title":"Infectious complications after CAR T-cell therapy: Mechanisms, risk stratification, and prevention","volume":"61","author":"Lee","year":"2026","journal-title":"Blood Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: Is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/s41375-025-02766-5","article-title":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma","volume":"39","author":"Frede","year":"2025","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hej-Ali, S., Banwell, K., Mohamed, H., Cervi, A., Dass, A., Gupta, R., Hamm, C., Kanjeekal, S., Strange Seguel, I., and Szalay, M. (2026). Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management. Cancers, 18.","DOI":"10.3390\/cancers18132083"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/bloodadvances.2025017366","article-title":"Infections after bispecific antibodies in B-cell lymphomas","volume":"10","author":"Kim","year":"2026","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Tix","year":"2024","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/hem3.29","article-title":"High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma","volume":"8","author":"Neill","year":"2024","journal-title":"Hemasphere"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and Infectious Syndromes Associated with Cancer Immunotherapies","volume":"69","author":"Fishman","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e14148","DOI":"10.1111\/tid.14148","article-title":"Infectious complications of car T-cell therapy: A longitudinal risk model","volume":"25","author":"Czapka","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Kikozashvili","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","article-title":"Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma","volume":"17","author":"Sesques","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: Timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/hematology.2024000535","article-title":"Mitigating and managing infection risk in adults treated with CAR T-cell therapy","volume":"2024","author":"Tabbara","year":"2024","journal-title":"Hematol.\/Educ. Program Am. Soc. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e14376","DOI":"10.1111\/tid.14376","article-title":"Infections following chimeric antigen receptor T cell therapy: 2018\u20132022","volume":"26","author":"Keri","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: A large database analysis","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Arya, S., and Shahid, Z. (2024). Overview of infectious complications among CAR T- cell therapy recipients. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1398078"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Evangelidis, P., Tragiannidis, K., Vyzantiadis, A., Evangelidis, N., Kalmoukos, P., Vyzantiadis, T.A., Tragiannidis, A., Kourti, M., and Gavriilaki, E. (2025). Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients. Pathogens, 14.","DOI":"10.3390\/pathogens14020170"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","article-title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","volume":"29","author":"Saini","year":"2023","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yin, L., Lv, B., Ge, J., Qi, Y., Xia, J., Ma, S., Wang, Y., Liu, Y., Zhou, D., and Cao, J. (2025). The impact of antibiotic use on outcomes of relapsed\/refractory multiple myeloma patients treated with CAR-T therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1566016"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"Prasad","year":"2025","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e91452b7","DOI":"10.1097\/01.HS9.0000972544.91452.b7","article-title":"P1414: CRP Is a Convenient Predictive Marker of the Antipyretic Effect of Tocilizumab on CRS During Car-T Cell Therapy","volume":"7","author":"Yokoyama","year":"2023","journal-title":"Hemasphere"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, J., Chen, H., Xu, C., Hu, M., Li, J., and Chang, W. (2024). Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1422591"},{"key":"ref_45","unstructured":"Shaikh, S., and Shaikh, H. (2025). CART Cell Therapy Toxicity. StatPearls, StatPearls Publishing."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2024-201519","article-title":"Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact","volume":"144","author":"Pei","year":"2024","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S2152-2650(24)01942-6","article-title":"P-039 CMV Reactivation During Treatment with Bispecific Antibodies for Relapsed\/Refractory Multiple Myeloma","volume":"24","author":"Jurgens","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-025-01393-8","article-title":"Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"15","author":"Jurgens","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/bloodadvances.2025016291","article-title":"Comparative Infection Risk in CAR T vs Bispecific Antibodies in B cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"9","author":"Easwar","year":"2025","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:15:42Z","timestamp":1788941742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":53,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182915"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182915","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}